文献速递临床试验与 GCP

加巴喷丁治疗间质性肺疾病相关难治性咳嗽的疗效:随机双盲安慰剂对照临床试验的研究方案

The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
PubMed 文献 · Trials · 2022-02-21

这是一项单中心、前瞻性、随机双盲安慰剂对照试验,计划纳入84例间质性肺疾病相关难治性咳嗽患者,按1:1随机分为口服加巴喷丁900 mg/日组与安慰剂组,疗程10周,自首次给药起随访14周。主要终点为14周时咳嗽症状评分变化,次要终点包括莱斯特生活质量问卷、胃食管反流病问卷、Hull气道反流问卷评分、咳嗽敏感性(C2和C5)值及安全性。

要点

  • 拟纳入84例间质性肺疾病相关难治性咳嗽患者,按1:1随机分组。
  • 干预为口服加巴喷丁900 mg/日,疗程10周,随访14周。
  • 主要终点为14周时咳嗽症状评分变化。

核心结论

  • 该研究将是首个探讨加巴喷丁治疗间质性肺疾病相关难治性咳嗽的随机对照临床试验,提供疗效、安全性和生活质量数据。
  • 若研究证实加巴喷丁有效改善间质性肺疾病相关难治性咳嗽,将提示深入理解其机制可能揭示新的治疗靶点。

研究设计与样本

  • 单中心、前瞻性、随机、双盲、安慰剂对照临床试验。
  • 计划纳入84例间质性肺疾病相关难治性咳嗽个体,按1:1比例随机分入两个治疗组。
  • 干预为口服加巴喷丁900 mg/日,疗程10周,自首次给药起随访共14周。

主要发现

  • 主要终点为14周时咳嗽症状评分的变化。
  • 次要终点包括莱斯特生活质量问卷(LCQ)、胃食管反流病问卷(Gerd Q)、Hull气道反流问卷(HARQ)评分的变化、咳嗽敏感性(C2和C5)值及安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Gabapentin, a neurotransmitter modulator, is thought to treat refractory cough associated with interstitial lung disease by improving cough hypersensitivity. METHODS/DESIGN: This is a single-center, prospective, randomized, double-blind, placebo-controlled trial. The trial will investigate the effect of a 10-week course of oral gabapentin 900 mg/day on refractory cough associated with interstitial lung disease (ILD) and explore the possible mechanisms involved in improving cough symptoms. A total of 84 individuals will be randomized in a 1:1 ratio to two treatment groups and will be followed for a total of 14 weeks from the first dose. The primary endpoint of the study will be the change in cough symptom scores at 14 weeks. The secondary endpoints include the change in Leicester Quality of Life Questionnaire (LCQ), Gastroesophageal Reflux Disease Questionnaire (Gerd Q), and Hull Airway Reflux Questionnaire (HARQ) scores; cough sensitivity (C2 and C5) values; and safety. DISCUSSION: This study will be the first randomized, controlled clinical trial to investigate gabapentin for the treatment of refractory cough associated with interstitial lung disease and provide data on efficacy, safety, and quality of life. If the study confirms that gabapentin is effective in improving refractory cough associated with interstitial lung disease, it will indicate that a deeper understanding of its mechanisms may reveal new therapeutic targets. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100045202 . Registered on 8 April 2021, www.chictr.org.cn.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gao R, Xu X, Wang S, et al. The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial. Trials. 2022. PMID: 35189953. doi:10.1186/s13063-022-06059-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。